Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022

GlobeNewswire November 30, 2022

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 9, 2022

Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2022

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary

GlobeNewswire November 7, 2022

Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures

GlobeNewswire November 3, 2022

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

GlobeNewswire November 1, 2022

Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

GlobeNewswire September 1, 2022

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2022

Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

GlobeNewswire August 8, 2022

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update

GlobeNewswire August 2, 2022

Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022

GlobeNewswire July 11, 2022

Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 27, 2022

Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering

GlobeNewswire June 22, 2022

Xenon Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire June 22, 2022

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

GlobeNewswire June 22, 2022

Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

GlobeNewswire June 21, 2022

Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 1, 2022

Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2022

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update

GlobeNewswire May 3, 2022

Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)

GlobeNewswire May 3, 2022